Carsten Hofmann Selected Research

gantenerumab

1/2022	In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model.
1/2022	Disease Modeling and Model-Based Meta-Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer's Disease.
1/2020	A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers.
12/2019	Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.
1/2018	Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
12/2017	A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carsten Hofmann Research Topics

Disease

6	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 12/2017
3	Schizophrenia (Dementia Praecox) 01/2016 - 10/2012
2	Edema (Dropsy) 01/2022 - 01/2022
1	Alcoholism (Alcohol Abuse) 01/2020
1	Injection Site Reaction 01/2020
1	Pain (Aches) 01/2020
1	Type 2 Diabetes Mellitus (MODY) 01/2019
1	Dizziness (Lightheadedness) 10/2012
1	Nausea 10/2012

Drug/Important Bio-Agent (IBA)

6	gantenerumabIBA 01/2022 - 12/2017
4	Amyloid (Amyloid Fibrils)IBA 01/2022 - 12/2019
2	Monoclonal AntibodiesIBA 01/2022 - 01/2020
2	Pharmaceutical PreparationsIBA 01/2020 - 01/2019
2	(4- (3- fluoro- 5- trifluoromethylpyridin- 2- yl)piperazin- 1- yl)(5- methanesulfonyl- 2- (2,2,2- trifluoro- 1- methylethoxy)phenyl)methanoneIBA 08/2013 - 10/2012
2	Glycine (Aminoacetic Acid)FDA LinkGeneric 08/2013 - 10/2012
1	aducanumabIBA 01/2022
1	bapineuzumabIBA 01/2022
1	Amyloid beta-PeptidesIBA 01/2022
1	Immunoglobulin G (IgG)IBA 01/2020
1	florbetapirIBA 12/2019
1	taspoglutideIBA 01/2019
1	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2019
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2016

Therapy/Procedure

1	Therapeutics 01/2022
1	Injections 01/2020
1	Subcutaneous Injections 01/2020